| Abstrakt: |
A study conducted by researchers at Umm Al-Qura University in Mecca, Saudi Arabia, reviewed the use and effectiveness of Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) inhibitors in heart diseases. The researchers analyzed 12 clinical trials involving PCSK-9 inhibitors and found that there is still controversy surrounding their effectiveness in patients with heart diseases. The majority of these trials were conducted in the US, and the researchers recommend conducting more randomized controlled clinical trials in this patient population. This study provides valuable insights into the use of PCSK-9 inhibitors in managing cardiac complications. [Extracted from the article] |
